ANIK

Anika Therapeutics Inc. (ANIK) | Rumor.io

Anika Therapeutics

ANIK

Attention (50-day avg)0%

Attention rank (50-day avg)#4,739

Bullish sentiment (50-day avg)100%

Price to earnings ratio-27.1

Market capitalization276.8M

Earnings per share-0.23

Dividend yield (TTM)—

Revenue (annual)112.8M

Net income (annual)-10.9M

Social

What share of all stock conversation is about ANIK?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Jul 30

Anika Therapeutics reported Q2 2025 revenue of $28.22M, a 32.69% year-over-year decline, but beat estimates.
The company's regenerative solutions business surged 41% in Q2 2025, with Integrity implants more than doubling in 2025.
Anika's Hyalofast clinical trial missed primary endpoints, but showed secondary benefits, with the company planning to submit a final FDA application by late 2025.

Generated by AI

Sentiment

Of the messages about ANIK that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	75% +33.7
Bearish	—	—	—	25% -33.7

Oct 25

Anika Therapeutics, Inc. (ANIK) has beaten earnings estimates and raised its FY19 guidance, with expected revenues of $112-113 million, a 6-7% increase.
The company's price has increased by $20 per share following the earnings beat, with some analysts predicting a 35-40% run and a stock price of $80-90.
ANIK's strong fundamentals, including a Piotroski-F score of 7.00 and an Altman-Z score better than the industry average, suggest a healthy and profitable company.

Generated by AI

Topics

Of the messages about ANIK that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	100%	100%	100%	5.88%
Announcements	0%	0%	0%	79.41%
Earnings	0%	0%	0%	5.88%
Controversies	0%	0%	0%	0%
Macro	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	8.82%

Analysts· Feb 22

Anika Therapeutics, Inc. (ANIK) was downgraded to Neutral by Sidoti with a price target of $41.
First Analysis downgraded ANIK to Neutral with a price target of $37.
Barrington Research cut ANIK's price target to $44.00, maintaining an outperform rating.

Announcements· Feb 26

Anika Therapeutics' Monovisc has been approved by the FDA, leading to a significant stock surge and a 43% gain in pre-market trading.
The approval is expected to enhance the company's market share and increase profitability, with a 69% product gross margin in the fourth quarter of 2013.
The FDA approval of Monovisc is seen as a positive development for the company, with analysts lifting their target price to $60 at Summer Street.

Generated by AI

Community

Of the messages about ANIK, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	18.46%
Newcomers	0%	0%	0%	81.54%

Regulars· Feb 21

Anika Therapeutics has issued a statement and will announce its fourth quarter and year-end 2022 financial results on Monday, March 6, 2023.
Caligan Partners has issued an open letter to Anika's board, criticizing the company's performance and acquisitions.
Anika's current structure is expected to result in minimal profits for the next two years, according to a critical assessment.

Newcomers· Jul 25

The newcomers are focused on the recent price movement of ANIK, with some noting unusual activity and others highlighting a price increase.
The newcomers are also interested in the volume of ANIK, with some posts alerting to increased trading activity and others noting a significant spike in volume.
The newcomers are discussing the company's recent earnings and business performance, specifically highlighting the revenue growth of CINGAL and the decision to advance the CINGAL program towards US regulatory approval.

Generated by AI

News

Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year?

Here is how Anika Therapeutics (ANIK) and Concentra Group (CON) have performed compared to their sector so far this year.

5d agoYahoo Finance Australia

B.Riley assumes Anika Therapeutics stock coverage with buy rating

11d agoInvesting.com

Anika (ANIK) Is a Great Choice for 'Trend' Investors, Here's Why

Anika (ANIK) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

1mo agoYahoo Finance

Anika Stock Gains 43.4% in the Past 3 Months: Here Is Why?

ANIK's strong sales momentum and raised 2026 guidance bolster investor confidence, while Cingal and Hyalofast advance its pipeline.

1mo agoYahoo Finance

Anika Therapeutics (ANIK) Is Up 11.10% in One Week: What You Should Know

Does Anika Therapeutics (ANIK) have what it takes to be a top stock pick for momentum investors? Let's find out.

1mo agoYahoo Finance

Zacks.com featured highlights include OptimumBank, EuroDry, Enova International, Anika Therapeutics and The GEO

Recent price strength puts OptimumBank, EuroDry, Enova International, Anika Therapeutics and GEO in focus as August stocks with momentum.

1mo agoYahoo Finance

Also Discussed

Investors talking about ANIK also mention

#	Name	Attention
1	AerCap Holdings N.V.AER	0%new
2	Jazz Pharmaceuticals plcJAZZ	0%0
3	8x8 Inc.EGHT	0%new
4	Genter Capital Taxable Quality Intermediate ETFGENT	0%0
5	Noah Holdings Limited Sponsored ADRNOAH	0%0
6	Patrick Industries, Inc.PATK	0%0
7	Methode Electronics, Inc.MEI	0%0
8	MacroGenics Inc.MGNX	0%0
9	CONN - Conn's, Inc.	——
10	Gentherm Inc.THRM	0%-0.01

Anika Therapeutics Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

Anika Therapeutics Inc. is a medical technology company focused on joint preservation and early intervention orthopedics. The company develops, manufactures, and commercializes hyaluronic acid-based products used in osteoarthritis pain management, regenerative medicine, sports medicine, and soft tissue repair. Its portfolio includes injectable therapies and orthopedic solutions designed to support mobility, tissue healing, and minimally invasive care for patients with degenerative joint conditions and musculoskeletal injuries. Anika Therapeutics serves healthcare professionals and clinical settings across the United States, Europe, and other international markets, with products used in orthopedics and related surgical applications. Headquartered in Bedford, Massachusetts, Anika Therapeutics Inc. plays a specialized role in the musculoskeletal care market by offering therapies and biomaterials that address joint health, cartilage repair, and recovery support.

Website

Location

32 Wiggins Avenue

Bedford, MA, 01730

United States

Social

What share of all stock conversation is about ANIK?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Jul 30

Anika Therapeutics reported Q2 2025 revenue of $28.22M, a 32.69% year-over-year decline, but beat estimates.
The company's regenerative solutions business surged 41% in Q2 2025, with Integrity implants more than doubling in 2025.
Anika's Hyalofast clinical trial missed primary endpoints, but showed secondary benefits, with the company planning to submit a final FDA application by late 2025.

Generated by AI

Sentiment

Of the messages about ANIK that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	75% +33.7
Bearish	—	—	—	25% -33.7

Oct 25

Anika Therapeutics, Inc. (ANIK) has beaten earnings estimates and raised its FY19 guidance, with expected revenues of $112-113 million, a 6-7% increase.
The company's price has increased by $20 per share following the earnings beat, with some analysts predicting a 35-40% run and a stock price of $80-90.
ANIK's strong fundamentals, including a Piotroski-F score of 7.00 and an Altman-Z score better than the industry average, suggest a healthy and profitable company.

Generated by AI

Topics

Of the messages about ANIK that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	100%	100%	100%	5.88%
Announcements	0%	0%	0%	79.41%
Earnings	0%	0%	0%	5.88%
Controversies	0%	0%	0%	0%
Macro	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	8.82%

Analysts· Feb 22

Anika Therapeutics, Inc. (ANIK) was downgraded to Neutral by Sidoti with a price target of $41.
First Analysis downgraded ANIK to Neutral with a price target of $37.
Barrington Research cut ANIK's price target to $44.00, maintaining an outperform rating.

Announcements· Feb 26

Anika Therapeutics' Monovisc has been approved by the FDA, leading to a significant stock surge and a 43% gain in pre-market trading.
The approval is expected to enhance the company's market share and increase profitability, with a 69% product gross margin in the fourth quarter of 2013.
The FDA approval of Monovisc is seen as a positive development for the company, with analysts lifting their target price to $60 at Summer Street.

Generated by AI

Community

Of the messages about ANIK, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	18.46%
Newcomers	0%	0%	0%	81.54%

Regulars· Feb 21

Anika Therapeutics has issued a statement and will announce its fourth quarter and year-end 2022 financial results on Monday, March 6, 2023.
Caligan Partners has issued an open letter to Anika's board, criticizing the company's performance and acquisitions.
Anika's current structure is expected to result in minimal profits for the next two years, according to a critical assessment.

Newcomers· Jul 25

The newcomers are focused on the recent price movement of ANIK, with some noting unusual activity and others highlighting a price increase.
The newcomers are also interested in the volume of ANIK, with some posts alerting to increased trading activity and others noting a significant spike in volume.
The newcomers are discussing the company's recent earnings and business performance, specifically highlighting the revenue growth of CINGAL and the decision to advance the CINGAL program towards US regulatory approval.

Generated by AI

Anika Therapeutics

Social

Jul 30

Oct 25

Analysts· Feb 22

Announcements· Feb 26

Regulars· Feb 21

Newcomers· Jul 25

Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year?

B.Riley assumes Anika Therapeutics stock coverage with buy rating

Anika (ANIK) Is a Great Choice for 'Trend' Investors, Here's Why

Anika Stock Gains 43.4% in the Past 3 Months: Here Is Why?

Anika Therapeutics (ANIK) Is Up 11.10% in One Week: What You Should Know

Zacks.com featured highlights include OptimumBank, EuroDry, Enova International, Anika Therapeutics and The GEO

Also Discussed

Anika Therapeutics Inc.

Company Information

Location

Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year?

B.Riley assumes Anika Therapeutics stock coverage with buy rating

Anika (ANIK) Is a Great Choice for 'Trend' Investors, Here's Why

Anika Stock Gains 43.4% in the Past 3 Months: Here Is Why?

Anika Therapeutics (ANIK) Is Up 11.10% in One Week: What You Should Know

Zacks.com featured highlights include OptimumBank, EuroDry, Enova International, Anika Therapeutics and The GEO

Also Discussed

Social

Jul 30

Oct 25

Analysts· Feb 22

Announcements· Feb 26

Regulars· Feb 21

Newcomers· Jul 25